0L8 Stock Overview Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Lantheus Holdings, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Lantheus Holdings Historical stock prices Current Share Price US$88.54 52 Week High US$114.30 52 Week Low US$46.59 Beta 0.46 1 Month Change -2.68% 3 Month Change -16.55% 1 Year Change 75.67% 3 Year Change 288.33% 5 Year Change 420.82% Change since IPO 1,336.40%
Recent News & Updates
Lantheus Holdings, Inc. (NasdaqGM:LNTH) announces an Equity Buyback for $250 million worth of its shares. Nov 21
Lantheus Holdings, Inc. (NasdaqGM:LNTH) announces an Equity Buyback for $250 million worth of its shares. Nov 20
Investor sentiment deteriorates as stock falls 26% Nov 13
Third quarter 2024 earnings released: EPS: US$1.89 (vs US$1.93 in 3Q 2023) Nov 08
Lantheus Holdings, Inc. Raises Earnings Guidance for the Full Year 2024 Nov 06
Lantheus Holdings, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 23 See more updates
Lantheus Holdings, Inc. (NasdaqGM:LNTH) announces an Equity Buyback for $250 million worth of its shares. Nov 21
Lantheus Holdings, Inc. (NasdaqGM:LNTH) announces an Equity Buyback for $250 million worth of its shares. Nov 20
Investor sentiment deteriorates as stock falls 26% Nov 13
Third quarter 2024 earnings released: EPS: US$1.89 (vs US$1.93 in 3Q 2023) Nov 08
Lantheus Holdings, Inc. Raises Earnings Guidance for the Full Year 2024 Nov 06
Lantheus Holdings, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 23
New major risk - Share price stability Oct 02
Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024 Sep 16
Lantheus Holdings, Inc. Appoints Julie Eastland as Board of Directors Sep 06
Second quarter 2024 earnings released: EPS: US$0.90 (vs US$1.38 in 2Q 2023) Aug 02
Lantheus Holdings, Inc. Maintains Revenue Guidance for the Full Year of 2024 Jul 31
Lantheus Holdings, Inc. to Report Q2, 2024 Results on Jul 31, 2024 Jul 17
Investor sentiment improves as stock rises 33% Jul 12
Lantheus Holdings, Inc. Appoints Jamie Spaeth as Chief People Officer Jul 08
Lantheus Holdings, Inc. Announces Management Appointments, Effective May 28, 2024 May 16 Lantheus Holdings, Inc. Revises Revenue Guidance for the Full Fiscal Year 202
First quarter 2024 earnings released: EPS: US$1.91 (vs US$0.041 loss in 1Q 2023) May 02
Lantheus Holdings, Inc., Annual General Meeting, Apr 25, 2024 Mar 16
Lantheus Holdings, Inc. Announces the FDA Approval of Definity (Perflutren Lipid Microsphere) for Pediatric Patients Mar 05
Full year 2023 earnings released: EPS: US$4.79 (vs US$0.41 in FY 2022) Feb 23
Lantheus Holdings, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2024 Feb 23 Lantheus Holdings, Inc. Announces CEO Changes, Effective March 1, 2024
Lantheus Holdings, Inc. Announces Acceptance of its First-to-File ANDA for Generic Lutathera (Lutetium Lu 177 Dotatate) Jan 11
Lantheus Holdings, Inc. Provides Revenue Guidance for Its Fiscal Year Ended December 31, 2023 Jan 10
Now 31% undervalued after recent price drop Dec 19
Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer Dec 19
Now 24% undervalued after recent price drop Nov 05
New major risk - Revenue and earnings growth Nov 04
Lantheus Holdings, Inc. Updates Earnings Guidance for the Full Year 2023 Nov 03
Third quarter 2023 earnings released: EPS: US$1.88 (vs US$0.89 in 3Q 2022) Nov 03 Lantheus Holdings, Inc. Elevates Robert J. Marshall, Jr. as Treasurer
New minor risk - Earnings quality Aug 07 Lantheus Holdings, Inc. Provides Revenue Guidance for the Third Quarter of Fiscal Year 2023
New minor risk - Share price stability Aug 04
Second quarter 2023 earnings released: EPS: US$1.38 (vs US$0.63 in 2Q 2022) Aug 03
Ratio Therapeutics Inc. In Collaboration with Lantheus and PharmaLogic, Announce First Patient Dosed in Phase I Study Evaluating a Novel FAP-Targeted Radiopharmaceutical for Pet Imaging Jul 12
Insufficient new directors Jul 02 Lantheus Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2023
First quarter 2023 earnings released: US$0.041 loss per share (vs US$0.63 profit in 1Q 2022) May 05
Full year 2022 earnings released: EPS: US$0.41 (vs US$1.06 loss in FY 2021) Feb 24
Investor sentiment improves as stock rises 16% Feb 23
Lantheus Holdings, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 18
Lantheus Holdings, Inc. Presents Data Reinforcing Real-World Clinical Utility of Piflufolastat F 18 PET Scanning in Men with Recurrent Prostate Cancer and Low PSA Levels Feb 17
Lantheus to Present Piflufolastat F 18 Data at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium Feb 09
Lantheus Holdings, Inc. (NasdaqGM:LNTH) acquired Cerveau Technologies, Inc. Feb 07
Lantheus Holdings, Inc. Appoints Amanda Morgan as Senior Vice President, Commercial Nov 30
Lantheus Announces the Approval of DEFINITY® (Perflutren Lipid Microsphere) by China’s NMPA Nov 29
Investor sentiment deteriorated over the past week Nov 10
Third quarter 2022 earnings released: EPS: US$0.89 (vs US$0.20 loss in 3Q 2021) Nov 04 Lantheus Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter 2022
GE Healthcare and Lantheus Holdings Inc Announces Phase III Clinical Trial Finds [¹8F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease Sep 14
Second quarter 2022 earnings released: EPS: US$0.63 (vs US$0.40 loss in 2Q 2021) Aug 05 Lantheus Holdings, Inc. Updates Earnings Guidance for the Full Year 2022
Lantheus Holdings, Inc.(NasdaqGM:LNTH) dropped from Russell Microcap Index Jun 26
Lantheus Holdings, Inc. Announces Executive Changes Jun 16 Lantheus’ PYLARIFY AI™ Platform Demonstrates Higher Efficiency and Consistency While Maintaining Accuracy for Assessment of PSMA Imaging in Prostate Cancer
Lantheus Holdings, Inc. Presents Results from a PYLARIFY AI™ Study at the American Urological Association (AUA) Annual Meeting May 18
Independent Director recently sold €71k worth of stock May 14
Lantheus Holdings, Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of NM-01 to Monitor PD-L1 Expression in Non-Small Cell Lung Cancer Patients May 14 Lantheus Holdings, Inc. Revises Earnings Guidance for the Full Year of Fiscal 2022
First quarter 2022 earnings released: EPS: US$0.63 (vs US$0.13 in 1Q 2021) May 01
Lantheus Holdings, Inc. Appoints Jean-Claude Provost as Interim Chief Medical Officer Apr 05
Principal Accounting Officer recently sold €104k worth of stock Mar 10
Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member Mar 03
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 25 Lantheus Holdings, Inc. Reports Impairment of Long-Lived Assets for the Fourth Quarter Ended December 31, 2021
Lantheus Holdings, Inc. Receives U.S. FDA Approval of New Manufacturing Facility Feb 24
Lantheus Announces PYLARIFY AI™ is Now Available Dec 01
Lantheus Holdings, Inc. Announces CMS Grants Transitional Pass-Through Payment for PYLARIFY® (piflufolastat F 18) Injection, Effective January 1, 2022 Nov 24
Third quarter 2021 earnings released: US$0.20 loss per share (vs US$0.096 loss in 3Q 2020) Nov 05 Lantheus Announces Addition of PSMA Pet Imaging Agent to the National Comprehensive Cancer Network® (Nccn) Guidelines for Prostate Cancer
Chief Operating Officer John Bolla has left the company Aug 11
Second quarter 2021 earnings released: US$0.40 loss per share (vs US$0.16 loss in 2Q 2020) Jul 29
Lantheus Holdings, Inc. Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection May 28
First quarter 2021 earnings released: EPS US$0.13 (vs US$0.085 in 1Q 2020) May 05 Lantheus Holdings, Inc. Provides Earnings Guidance for the Second Quarter 2021 Lantheus Holdings, Inc. Announces Resignation of Fredrick Robertson from the Board
Lantheus Holdings, Inc. Announces Publication of PyL™ (18F-DCFPyL) Results from Pivotal Studies Mar 03
Full year 2020 earnings released: US$0.25 loss per share (vs US$0.81 profit in FY 2019) Feb 28
Revenue beats expectations Feb 28
New 90-day high: €14.90 Feb 06
Lantheus Holdings, Inc. and PharmaLogic Holdings Corp. Enter into A Long-Term Supply Agreement Feb 02
Lantheus Holdings, Inc. Announces Submission of Drug Master File for NM-01 in the U.S Jan 13 Shareholder Returns 0L8 DE Medical Equipment DE Market 7D -2.4% 1.5% 2.6% 1Y 75.7% -6.0% 13.4%
See full shareholder returns
Return vs Market: 0L8 exceeded the German Market which returned 12.1% over the past year.
Price Volatility Is 0L8's price volatile compared to industry and market? 0L8 volatility 0L8 Average Weekly Movement 8.4% Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.5% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 0L8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 0L8's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer.
Show more Lantheus Holdings, Inc. Fundamentals Summary How do Lantheus Holdings's earnings and revenue compare to its market cap? 0L8 fundamental statistics Market cap €6.20b Earnings (TTM ) €416.11m Revenue (TTM ) €1.46b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0L8 income statement (TTM ) Revenue US$1.50b Cost of Revenue US$533.18m Gross Profit US$963.62m Other Expenses US$536.00m Earnings US$427.61m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 6.15 Gross Margin 64.38% Net Profit Margin 28.57% Debt/Equity Ratio 47.8%
How did 0L8 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/17 13:15 End of Day Share Price 2025/01/17 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Lantheus Holdings, Inc. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jeffrey Johnson Baird Yuan Zhi B. Riley Securities, Inc. Brian Kemp Dolliver Brookline Capital Markets
Show 21 more analysts 
